Price
$0.2289
Decreased by -0.48%
Dollar Volume (20D)
49.36 K
ADR%
10.98
Earnings Report Date (estimate)
Sep 12, 23 (N/A)
Market Cap.
22.19 M
Shares Float
67.68 M
Shares Outstanding
96.94 M
Beta
0.01
Price / Earnings
-1.43
BPR
0.18
20D Range
0.21 0.30
50D Range
0.21 0.54
200D Range
0.21 1.19
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Sep 13, 23 0.04
Increased by +233.33%
0.04
Increased by +14.29%
Jul 27, 23 0.03
Increased by +175.00%
0.02
Increased by +33.33%
Mar 15, 23 -0.06
Decreased by -100.00%
-0.04
Decreased by -50.00%
Dec 12, 22 -0.03
Increased by +25.00%
-0.02
Decreased by -25.00%
Sep 13, 22 -0.03 -0.07
Increased by +57.14%
Jul 19, 22 -0.04 -0.03
Decreased by -33.33%
Mar 15, 22 -0.03 -0.02
Decreased by -50.00%
Dec 13, 21 -0.04 -0.03
Decreased by -60.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Apr 30, 23 0.00
Decreased by N/A%
-3.31 M
Increased by +14.50%
Decreased by N/A%
Decreased by N/A%
Jan 31, 23 0.00
Decreased by N/A%
-5.43 M
Decreased by -108.32%
Decreased by N/A%
Decreased by N/A%
Oct 31, 22 0.00
Decreased by N/A%
-3.11 M
Increased by +13.51%
Decreased by N/A%
Decreased by N/A%
Jul 31, 22 0.00
Decreased by N/A%
-3.04 M
Decreased by -30.98%
Decreased by N/A%
Decreased by N/A%
Apr 30, 22 0.00
Decreased by N/A%
-3.87 M
Decreased by -207.60%
Decreased by N/A%
Decreased by N/A%
Jan 31, 22 0.00
Decreased by N/A%
-2.61 M
Decreased by -132.86%
Decreased by N/A%
Decreased by N/A%
Oct 31, 21 0.00
Decreased by N/A%
-3.60 M
Decreased by -165.85%
Decreased by N/A%
Decreased by N/A%
Jul 31, 21 0.00
Decreased by N/A%
-2.32 M
Decreased by -76.18%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.